非洲抗疟药耐药性:暴风雨前的宁静?
本文综述了非洲抗疟药耐药性的演变模式:氨基喹啉类和抗叶酸类药物的耐药性长期存在,但随着氯喹使用大幅减少,氯喹耐药率已下降;青蒿素联合疗法在非洲尚未构成实质问题,但东南亚已出现耐药,非洲需高度警惕并持续监测。
要点
- 氯喹耐药率随其使用减少而下降,但抗叶酸类耐药仍广泛存在。
- 青蒿素联合疗法在非洲目前未构成实质耐药问题。
- 非洲若出现青蒿素联合疗法耐药,后果可能极其严重,需持续监测。
核心结论
- 非洲青蒿素联合疗法耐药目前不构成实质问题,但一旦出现可能造成毁灭性后果,持续监测是高度优先事项。
研究设计与样本
- 本文为综述,总结非洲抗疟药耐药性的演变模式,未报告系统检索范围或样本量。
主要发现
- 氨基喹啉类和抗叶酸类药物的耐药性长期存在。
- 随着氯喹治疗疟疾的使用大幅减少,氯喹耐药率已下降。
- 抗叶酸类耐药仍广泛存在,该类药物在某些场景用于预防疟疾。
- 青蒿素联合疗法是非洲疟疾标准治疗,其耐药已在东南亚出现。
- 目前非洲对青蒿素或联合疗法中关键配伍药物的耐药似乎不是实质问题。
临床怎么用
- 非洲应持续监测青蒿素联合疗法耐药性的出现,将其作为高度优先事项。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antimalarial drug resistance, in particular resistance to Plasmodium falciparum, challenges the treatment and control of malaria. In this Review, we summarise evolving patterns of antimalarial drug resistance in Africa. Resistance to aminoquinolines and antifolates is long-standing, yet with greatly decreased use of chloroquine to treat malaria, the prevalence of resistance to chloroquine has decreased. Resistance to antifolates, which are used to prevent malaria in some settings, remains widespread. Resistance to artemisinin-based combination therapies, the standard treatments for malaria in Africa, has emerged in southeast Asia. At present, resistance to artemisinins or key partner drugs included in combination therapies does not appear to be a substantial problem in Africa. However, emergence of resistance to artemisinin-based combination therapies in Africa would probably have devastating consequences, and continued surveillance for the emergence of resistance on this continent is a high priority.
引用
- Conrad MD, Rosenthal PJ. Antimalarial drug resistance in Africa: the calm before the storm? Lancet Infect Dis. 2019. PMID: 31375467. doi:10.1016/S1473-3099(19)30261-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。